Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Infections in Patients With Cytokine Release Syndrome/Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell Therapy.

Open forum infectious diseases·2026
Same author

Varnimcabtagene autoleucel (ARI-0001) in relapsed or refractory mantle cell lymphoma.

HemaSphere·2026
Same author

The European CAR-T map-Current status and future directions to improve access to CAR T-cell therapy for hematologic malignancies.

HemaSphere·2026
Same author

Operational burden and fragmented implementation in CAR T-cell therapy: Insights from a multinational survey by the GoCART Coalition and the JACIE Quality Managers Committee.

HemaSphere·2025
Same author

CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia.

Journal of cellular and molecular medicine·2025
Same author

Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe.

Blood advances·2025

Related Experiment Video

Updated: Jun 27, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.0K

InsT-ALLing CD7 chimeric antigen receptors before transplantation.

Julio Delgado1

  • 1Hospital Clínic de Barcelona, FCRB-IDIBAPS, University of Barcelona, Barcelona, Spain.

British Journal of Haematology
|April 27, 2024
PubMed
Summary

Chimeric antigen receptor T-cell therapy targeting CD7 shows promise as a bridge to allogeneic stem cell transplant for T-cell acute lymphoblastic leukemia/lymphoma.

Keywords:
CD7 CARsT‐ALLallogeneic haematopoietic cell transplantation

More Related Videos

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

2.6K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K

Related Experiment Videos

Last Updated: Jun 27, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.0K
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

2.6K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K

Area of Science:

  • Hematology
  • Immunotherapy
  • Oncology

Background:

  • Relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) has limited treatment options.
  • Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a potential curative therapy.
  • Bridging T-ALL/LBL patients to allo-HSCT remains challenging.

Purpose of the Study:

  • To evaluate the safety and efficacy of CD7-targeted chimeric antigen receptor T-cell (CAR-T) therapy.
  • To assess CAR-T therapy as a bridge to allo-HSCT in T-ALL/LBL.
  • To analyze outcomes in patients achieving complete remission post-CAR-T therapy.

Main Methods:

  • Retrospective analysis of patients with relapsed/refractory T-ALL/LBL.
  • Administration of autologous CD7 CAR-T cell therapy.
  • Subsequent allogeneic haematopoietic stem cell transplantation in eligible patients.

Main Results:

  • CD7 CAR-T therapy facilitated successful bridging to allo-HSCT in a subset of patients.
  • Achieving complete remission post-CAR-T therapy was associated with improved transplant outcomes.
  • Safety profile of CD7 CAR-T therapy requires careful monitoring.

Conclusions:

  • CD7 CAR-T therapy represents a viable strategy for T-ALL/LBL patients needing allo-HSCT.
  • Further research is warranted to optimize CAR-T therapy protocols and patient selection.
  • This approach offers a potential pathway for durable remission in challenging T-ALL/LBL cases.